Less Than 20 Percent of Patients Diagnosed with the Disease Receive Pharmacotherapy Within a Year of Their Diagnosis, According to a New Report
From Decision Resources
WALTHAM, Mass., April 7, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Boehringer Ingelheim's Flomax, also marketed as Astellas's Harnal in Japan, is the physician's drug of choice for newly diagnosed benign prostatic hyperplasia patients. Garnering more patient share than any other alpha blocker in first- and second-line therapy for benign prostatic hyperplasia, Flomax holds a 55.2 percent first-line patient share, compared with 12.4 percent for Sanofi-Aventis's Uroxatral, 4.8 percent for doxazosin (Pfizer's Cardura/Cardura XL, generics), and 4.3 percent for terazosin (Abbott's Hytrin, generics).
"Flomax stands out among alpha blockers thanks to its lower propensity to induce orthostatic hypotension, despite evidence of a high incidence of retrograde ejaculation and higher cost relative to generic agents in this class", said Nathan Calloway, analyst at Decision Resources. "However, rather than calling attention to Flomax's side-effect/safety profile, the highest proportion of urologists we surveyed (83 percent) rank familiarity with the drug as an important reason to choose Flomax over Uroxatral, whereas the largest percentage of primary care physicians (66 percent) believe that Flomax's reimbursement and formulary position is a key advantage over Uroxatral's."
The report entitled Treatment Algorithms in Benign Prostatic Hyperplasia also finds that slightly less than one-fifth (18.9 percent) of newly diagnosed benign prostatic hyperplasia patients receive pharmacological treatment within one year of their initial diagnosis. Primary care physicians and urologists surveyed suggest that patient reluctance to take drugs that are associated with side effects such as retrograde ejaculation, decreased libido, and hypotension as well as patients' belief that symptoms will go away on their own are key reasons for the low drug-treatment rate.
About Treatment Algorithm Insight Series
Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.
For each disease examined, Decision Resources' Treatment Algorithm
Insight Series provide the following:
-- Summary of U.S. medical practice based on interviews with leading
experts in the field.
-- Qualitative diagnosis/referral/treatment algorithm for the United
-- Drug usage by lines of therapy (1st, 2nd, 3rd line).
-- Discussion of key freeform combinations by lines of therapy.
-- Product share (class and specific compound level) within each line of
therapy (1st, 2nd, 3rd line).
-- Progression of therapy from key 1st line products.
-- Pathway to key therapies from previous therapies.
-- Qualitative analysis of two-year forecast incorporating upcoming
launches, changes in reimbursement, etc.
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources, Inc.
|SOURCE Decision Resources|
Copyright©2008 PR Newswire.
All rights reserved